F0056
FISH for AML Panel (Any 5 Markers)
Number of Tests | 5 |
Test Included | t(8;21)(q22;q22), t(15;17)(q24;21), inv(16) or t(16;16), inv 3, Del 5q, Del 7q, MLL amplification, BCR/ABL t(9;22) fusion |
Test Details: Acute Myelogenous Leukaemia/Myelodysplastic syndrome is a group of heterogeneous hematologic conditions with characteristic chromosome abnormalities leading to specific gene rearrangements. Fluorescence in situ hybridization (FISH) is a sensitive method to detect smaller genomic changes associated with various haematological malignancies and solid tumours. Chromosomal abnormalities correlate with the prognosis and therapy. Currently, cytogenetic results allow stratification of patients with AML into 3 classes favourable, intermediate and unfavourable, according to clinical prognosis that is reported in literature. So, patients with t(8;21)(q22;q22) [RUNX1/RUNX1T1],inv(16)(p13;q22) [CBFB/MYH11] and t(15;17)(q24;q21) [PML/RARA] have favourable prognosis with good response to treatment and complete remissions. FISH studies are useful adjuncts to complete chromosomal studies.
Category
Cytogenetics
Pre-test Information
Clinical history, CBC report and treatment status of the patient is mandatory.
Report Delivery
4 working days
Gender
All
Organ
Blood / Bone Marrow
FISH for AML Panel (Any 5 Markers)
9000
Most Searched Diagnostic Tests